ArticleActa ophthalmologica2026
Long-term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate long-term outcomes of anti-VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry.
methodsThe cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow-up through 31 October 2023. Long-term follow-up (>5 years) was conducted for 7631 eyes. Statistical comparisons and multivariate logistic regression analysed differences between treatment failure and long-term treatment, treatment effectiveness, drug efficacy and predictive factors.
resultsThe relative risk of nAMD in females was 1.45. By the last follow-up, 17 518 (48.6%) patients discontinued treatment due to patient-related factors, 7202 (20.0%) due to treatment failure, 6285 (17.4%) for other reasons and 5065 (14.0%) due to death or clinical complications. Long-term patients were significantly younger, more of them were previously treated, received fewer injections per year and had better baseline BCVA and lower CRT than the failure group. Females and previously treated patients had a higher likelihood of long-term therapy, while older age and initial ranibizumab treatment increased the risk of failure. Patients with an initial BCVA >0.4 logMAR had significantly worse BCVA outcomes, while CRT and treatment strategy showed no significant differences. Introduction of programme exclusion if treatment gap >4 months reduced long breaks, increased injection numbers, slightly lowered BCVA and had no significant effect on CRT.
conclusionEarly visual acuity response, drug choice (aflibercept), and healthcare system modifications influence long-term success and adherence in nAMD management. While systemic changes improved continuity and injection frequency, they did not enhance visual outcomes, highlighting the need for individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.